Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Orient EuroPharma Co., Ltd. and Debiopharm Group™ have jointly announced the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia.
Orient EuroPharma and Debiopharm have announced the launch of Pamorelin® in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.
Mr.JP. Chang, President of Pharmaceutical Business Unit, Orient EuroPharma said that “it is great to cooperate with Debiopharm Group™ for introducing the new drug to South East Asian territories. Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients”.
“This collaboration opens up an important new market for our backbone therapy of advanced prostate cancer (locally advanced and metastatic)” said Thierry Mauvernay, Delegate of the Board, Debiopharm Group. “After successful launch in 74 countries, we look forward to bringing Pamorelin® to several South East Asian markets, together with Orient EuroPharma”.